Skip to content

Dermosep-I

Application of Dermofural ointment in patients with septic burns.

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
RPCEC
Registry ID
RPCEC00000040
Enrollment
20
Registered
2010-12-20
Start date
2008-05-02
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic burns.

Interventions

One single group will have lesions treated with Dermofural ointment once a day, after bandage removal and wound bath. Depending on the patient’s clinical and microbiological evolution, Dermofural can
Anti-Bacterial Agents
Anti-Infective Agents
Dermofural

Sponsors

Center for Genetic Engineering and Biotechnology (CIGB)
Lead Sponsor
Chemical Bioactive Center. ''Marta Abreu'' Central University of Las Villas
Collaborator

Eligibility

Sex/Gender
All
Age
16 Years to 60 Years

Inclusion criteria

Inclusion criteria: Cuban patients, of both sexes and any race, with burns type A, AB or B, classified as slight, moderate or serious, requiring occlusion. Presence of sepsis, microbiologically confirmed in lesions, caused by Pseudomonas aeruginosa or any other bacterial agents. Patients aged 16 to 60. Burns by physical agents. Patient’s Informed Consent in writing to participate in the trial and undergo relevant tests.

Exclusion criteria

Exclusion criteria: Burns by electrical or chemical agents, inhalation, or both. Burns in anal and genital region, and face. Systemic or topical anti-microbial required. Patients who have been on steroid treatment in the last 3 months (any administration route). History of allergy or hypersensitivity to any formulation component. Diabetes mellitus. Immune disease diagnosed. Malignant neoplasia. Chronic kidney failure or liver disorder. Collagen disease. Pregnancy, breastfeeding or puerperium. Severe psychiatric disorder or mental handicap.

Design outcomes

Primary

MeasureTime frame
Treatment safety, measuring time: 28 days.

Secondary

MeasureTime frame
Clinical and microbiological response to sepsis, measuring time: 28 days. Negative microbiological test, measuring time: 28 days. Sepsis elimination, measuring time: 28 days. Lesion cicatrization: measuring time: 28 days. Lesion size: measuring time: 28 days

Countries

Cuba

Contacts

Public ContactIdrian Garcia Garcia

Clinical Trials Division, Center for Biological Research

idrian.garcia@cigb.edu.cu

Outcome results

None listed

Source: RPCEC (via WHO ICTRP) · Data processed: Apr 4, 2026